Seaport Therapeutics, Inc. Expense Breakdown
No Expense Breakdown for SPTX on this site yet.
- 2026-06-30: GlyphAllo Direct Research and Development Expenses $12.80M; GlyphAgo Direct Research and Development Expenses $3.48M; Glyph2BLSD Direct Research and Development Expenses $1.62M.
- 2025-06-30: GlyphAllo Direct Research and Development Expenses $4.75M; GlyphAgo Direct Research and Development Expenses $2.01M; Glyph2BLSD Direct Research and Development Expenses $1.55M.
Source checked: the stored Expense Breakdown page for SPTX.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | GlyphAllo Direct Research and Development Expenses | GlyphAgo Direct Research and Development Expenses | Glyph2BLSD Direct Research and Development Expenses |
|---|---|---|---|
| 2026-06-30 | $12.80M | $3.48M | $1.62M |
| 2025-06-30 | $4.75M | $2.01M | $1.55M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |